The Zhitong Finance App learned that on July 3, the European Medicines Agency (EMA) approved Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) and Sanofi (Sanofi)'s major treatment Dupixent (dupilumab) as an additional maintenance treatment to treat adult patients with chronic obstructive pulmonary disease (COPD) characterized by elevated blood eosinophils and not controlled. The approval applies to patients who are already using a combination of inhaled corticosteroids (ICS), long-acting beta-2-receptor agonists (LABA), and long-acting muscarinic antagonists (LAMAs), or in combination therapy with LABA and LAMA where ICS is not appropriate.

According to the press release, Dupixent is the first new treatment approved for COPD in the European Union in more than a decade. This is also the first time that Dupixent has been approved by global regulators to treat COPD. Currently, the treatment is being reviewed by regulators around the world, including the US, China, and Japan.